Table 1.
Baseline demographical and clinical characteristics
| Placebo (n = 301) | Fesoterodine (n = 308) | |
|---|---|---|
| Sex, n (%) | ||
| Male | 57 (19) | 55 (18) |
| Female | 244 (81) | 253 (82) |
| Mean (SD) age, y | 58.2 (13.2) | 57.3 (13.4) |
| Race, n (%) | ||
| White | 246 (81.7) | 251 (81.5) |
| Black | 37 (12.3) | 38 (12.3) |
| Asian | 8 (2.7) | 8 (2.6) |
| Other | 10 (3.3) | 11 (3.6) |
| Mean weight, kg (range) | 81.5 (45.8–156.0) | 81.3 (45.0–194.1) |
| Mean (SD) body-mass index, kg/m2 | 30.0 (6.9) | 29.8 (6.7) |
| Mean duration since OAB diagnosis, y (range) | 6.6 (0.5–50.1) | 7.0 (0.5–46.5) |
| Median duration since diagnosis, y* | 4.6 | 4.7 |
| OAB symptoms at baseline, mean (SD)† | ||
| UUI episodes/24 h | 3.83 (2.5) | 3.93 (2.5) |
| Micturitions/24 h | 12.48 (3.8) | 12.44 (3.6) |
| Urgency episodes/24 h | 11.26 (4.0) | 11.38 (4.0) |
Data for subjects who were randomised and received double-blind treatment, except where noted.
*
Data for randomised subjects (placebo, n = 320; fesoterodine, n = 322).
†
Data for the full analysis set of subjects with symptom and change from baseline to week 12 (LOCF) data (placebo, n = 279; fesoterodine, n = 292). OAB, overactive bladder.